Home Forums |
#1
|
|||
|
|||
Pretreamtent for aggressive MDS?
I really hope I get some sort of response from this post because I am desperate. The bad news keeps coming and I received results that my dad is positive for FLT3-ITD which makes for an aggressive disease. Some websites I have visited said it wasn't a bad progrosis but others say it's a bad prognosis. Maybe the Cuadra's know about this new drug Sorafenib that can be used to suppress this mutation? I have read that taking it before and after transplant can be very beneficial. Has anyone taken this drug before? Please someone out there give me some hope! I love my dad so much and I want him to be around for a long time.
__________________
Daughter of father diagnosed with MDS RAEB-II intermediate risk due to normal cytogenetics. Blasts at 13% peripheral blood at diagnosis with no cytopenias. 6 cycles on Vidaza then on to SCT at Duke. BMT from my brother and now showing signs of relapse. DLI in the works. |
#2
|
|||
|
|||
Quote:
Sorafenib (brand name Nexavar), combined with chemotherapy, attempts to eliminate cancer cells in multiple ways: targeting both internal cell components and surface enzymes, some of which may inhibit the cell's ability to form blood vessels. There are open clinical trials for sorafenib. It's one of many drugs that have been studied for FLT3-ITD, but that's not the only drug of its type. The overview for a clinical trial for ponatinib (trade name Iclusig) in France describes sorafenib as a "first generation FLT3 inhibitor" while also mentioning "second generation" and "third generation" inhibitors. A good next step might be to seek advice from an AML expert on specific trials to consider. With your dad's unique history, it'll be hard for you to tell what trials he'd qualify for and which would be most promising for him. I suggest that you not rule anything out until you consult one or more doctors who treat AML. |
#3
|
|||
|
|||
Quote:
__________________
Daughter of father diagnosed with MDS RAEB-II intermediate risk due to normal cytogenetics. Blasts at 13% peripheral blood at diagnosis with no cytopenias. 6 cycles on Vidaza then on to SCT at Duke. BMT from my brother and now showing signs of relapse. DLI in the works. |
#4
|
|||
|
|||
I have heard of others on a trial for ASP2215, so you might ask about it. There are several threads anout it on daily strength under the AML forum. Althought most of those taking it do not have MDS the do have the same AML mutation as your father.
__________________
Mother of 34 year old son who was diagnosed with MDS & AML at the same time. He underwent induction and 3 rounds of consolidation before having a MUD SCT on 8/28/14. |
Thread Tools | Search this Thread |
|
|
Similar Threads | ||||
Thread | Thread Starter | Forum | Replies | Last Post |
MDS - VA assigns diagnostic code 7725 | Tommy Daniels | MDS | 4 | Sun Jan 22, 2017 04:51 PM |
New Tool: MDS Classification | Marrowforums | Site Announcements | 7 | Tue Jan 4, 2011 06:12 AM |
Battle with MDS - A successful story | informer | Alternative Treatments | 4 | Sat May 22, 2010 09:26 AM |